AbbVie (ABBV) CEO Gonzalez: We Will be Active in M&A, Aim to Mitigate Biosimilar Impact

AbbVie (NYSE: ABBV) CEO Richard Gonzalez spoke at a Goldman Sachs Healthcare CEOs Unscripted Conference today. In part, the exec said:

-- FY15 will be a 'very strong' growth year for AbbVie
-- FY17 - 20 pipeline prospects look good
-- Daclizumab wlll be a 'meaningful' product for the company
-- Humira for HS to be $500 - $1 billion product
-- The company is working on formulation enhancements for Humira
-- AbbVie will be able to moderate impacts of biosimilars
-- The company will continue to be active in M&A

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• What's next for natural gas prices? Goldman Sachs weighs in
• AbbVie (ABBV): New Data Show RINVOQ Demonstrated Superiority Versus DUPIXENT Across Primary and All Secondary Endpoints